Detalhe da pesquisa
1.
Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background.
Int J Mol Sci
; 25(5)2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38474294
2.
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
Breast Cancer Res
; 24(1): 71, 2022 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307826
3.
Predictive modeling of gene expression regulation.
BMC Bioinformatics
; 22(1): 571, 2021 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34837938
4.
Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Mol Cancer
; 16(1): 97, 2017 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28558767
5.
Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.
Connect Tissue Res
; 56(5): 355-63, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25943461
6.
Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair.
Cancers (Basel)
; 15(17)2023 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37686585
7.
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment.
Front Oncol
; 12: 903016, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35719948
8.
Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells.
Cancers (Basel)
; 14(7)2022 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35406579
9.
Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas.
Ther Adv Med Oncol
; 14: 17588359221095064, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665077
10.
Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment.
Front Oncol
; 12: 903536, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35912188
11.
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
J Hematol Oncol
; 14(1): 186, 2021 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34742344
12.
Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy.
Cancers (Basel)
; 12(8)2020 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32718079
13.
Impact of ERCC1, XPF and DNA Polymerase ß Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts.
Cancers (Basel)
; 12(9)2020 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32847049
14.
A circular RNA map for human induced pluripotent stem cells of foetal origin.
EBioMedicine
; 57: 102848, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32574961
15.
LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.
J Thorac Oncol
; 15(3): 360-370, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31634668
16.
Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer.
Am J Cancer Res
; 10(2): 572-580, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32195028
17.
Downregulation of class II phosphoinositide 3-kinase PI3K-C2ß delays cell division and potentiates the effect of docetaxel on cancer cell growth.
J Exp Clin Cancer Res
; 38(1): 472, 2019 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31752944
18.
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.
Oncotarget
; 9(37): 24707-24717, 2018 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29872499
19.
Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Oncotarget
; 8(5): 7441-7451, 2017 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-26910918
20.
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
Neoplasia
; 19(1): 35-42, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27988457